#ASCO25 is around the corner, and it’s inspiring to see the growing momentum for #ILC research at major meetings. Just a few years ago, ILC had little to no visibility @ASCO, this year, 7 ILC abstracts will be presented. Here is a brief overview of each: 1. Macroscale Genomic Alterations in Histomolecular ILC [Poster #1049; Jason A. Mouabbi, MD (MD Anderson)] @JAMouabbi @MDAndersonNews Key Findings: Whole-exome sequencing of 617 samples showed unique CNV patterns and enriched APOBEC activity in histomolecular ILC. These tumors had lower HRD but higher TMB compared to NST, suggesting therapeutic vulnerabilities 2. Neoadjuvant Endocrine Therapy (NAET) vs. Chemotherapy (NAC) in Stage II–III ILC [Poster #603; Jason A. Mouabbi (MD Anderson)] @JAMouabbi @MDAndersonNews Key Findings: In this large retrospective study, NAET have shown great promise as a appropriate alternative to NAC in ILC 3. Serial ctDNA Monitoring in Early-Stage HR+/HER2− ILC [Poster #581; Julia Foldi, MD (UPMC)] @JuliaFoldiMD @oesterreichs @Adrianvlee @UPMCnews @MageeWomens Key Findings: In a cohort of 430 patients, longitudinal ctDNA positivity correlated strongly with distant recurrence, with a 31-fold increased risk when ctDNA was positive within 2 years of surgery. PIK3CA was the most frequent co-mutation with CDH1. 4. ALTTO Trial Subgroup Analysis: HER2+ ILC [Poster #542; Guilherme Nader Marta, MD (Dana-Farber)] @GuiNaderMarta @DFCI_BreastOnc Key Findings: Among 61 HER2+ ILC patients from the ALTTO trial, long-term survival outcomes were comparable to NST, but CNS relapse was significantly higher in ILC (13.6% vs. 5.0%), highlighting unique metastatic behavior. 5. Patient Experiences in ILC Diagnosis and Treatment [Poster #11111; Astrid Quirarte (UCSF)] @UCSF Key Findings: Qualitative analysis from a prospective registry revealed diagnostic delays due to mammographically occult disease, misclassification, and underestimation of tumor size, underscoring the need for ILC-specific clinical approaches 6. Impact of Surgery Type on Mortality in Unilateral ILC [Poster @585; Richa Jaiswal, MD (Women’s College Hospital)] @DavidLimMD @WCHospital Key Findings: SEER-based analysis of 58,861 patients found that bilateral mastectomy reduced contralateral breast cancer risk and was associated with a modest but significant reduction in breast cancer mortality compared to lumpectomy 7. Treatment Patterns and Genomic Landscape of Metastatic ILC [Poster #1119; Sherry Shen, MD (MSKCC)] @SherryShenMD @FresiaPareja @jhaveri_komal @MSKCancerCenter Key Findings: In a large single-institution cohort (n=654), OS differed significantly by PIK3CA, PTEN, and CDH1 mutation status, emphasizing the prognostic relevance of NGS in metastatic ILC @LobularBCA @elbcc